a The Royal Marsden NHS Foundation Trust , London , UK.

Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer.

Published in Expert Opinion on Investigational Drugs

Introduction: Immunotherapy has revolutionized the treatment of cancer. Given this growing success, at the same time, there are significant limitations and unanswered questions concerning response rates, duration of therapy, why some patients respond and others do not, and if combining different immune-agents would overcome this lack of response, i...